Waldenström Macroglobulinemia Symptoms May be Gastro-Related
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
WM patients with high CXCR4S338X clonality had worse outcomes after ibrutinib therapy compared with patients who had low CXCR4S338X clonality.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.
A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.
Concurrent CXCR4 and MYD88 L265P mutations were found to occur in patients with Waldenström macroglobulinemia.
More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.